ndtvprofit39m
Dr Reddy's Share Price Rises As Analysts Upgrade Rating, Hike Target Price
Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...
Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Dr Reddy’s Financials Verified; Investor Confidence Boosted
Dr Reddy’s Laboratories (RDY) has released an update. Dr Reddy’s Laboratories’ recent financial review by Ernst & Young ...
Business Insider18h
Dr. Reddy’s Laboratories Reports Q2 Revenue Growth
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by strong ...
cnbctv184h
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Shares of Dr. Reddy's Laboratories Ltd. will be closely watched in Wednesday's trading as its revenue for the September ...
Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
ndtvprofit3h
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
Dr Reddys Stocks: Dr. Reddy's Laboratories ended the previous trading day at Rs 1272.20.
Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...
Dr. Reddy’s to expand GLP-1 portfolio with focus on obesity and diabetes drug markets
With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...
Dr Reddy's Q2 performance sees revenue boost, but challenges persist
Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong ...
Dr Reddy’s clocks 16.51% increase in Q2 revenues
New Delhi: Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended September 30 ...